|1.||Rosen, Hugh: 20 articles (01/2016 - 04/2004)|
|2.||Hla, Timothy: 16 articles (04/2015 - 04/2004)|
|3.||Chun, Jerold: 15 articles (05/2015 - 04/2004)|
|4.||Proia, Richard L: 11 articles (04/2015 - 04/2004)|
|5.||Brinkmann, Volker: 9 articles (11/2014 - 12/2003)|
|6.||Takuwa, Yoh: 9 articles (11/2013 - 09/2003)|
|7.||Chiba, Kenji: 9 articles (01/2013 - 12/2005)|
|8.||Lynch, Kevin R: 7 articles (06/2015 - 01/2007)|
|9.||Takuwa, Noriko: 7 articles (11/2013 - 09/2003)|
|10.||Gonzalez-Cabrera, Pedro J: 6 articles (01/2016 - 05/2011)|
10/15/2014 - "The aim of this study was to assess in healthy subjects the safety, tolerability, pharmacokinetics, and pharmacodynamics of ponesimod, an oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator in development for multiple sclerosis, by using an uptitration scheme up to supratherapeutic doses. "
02/28/2010 - "Moreover, the differential effect of FTY720-P on S1P1 receptor regulation has been suggested to be the mechanism of action of this drug, which is now in Phase III clinical trials for the treatment of multiple sclerosis. "
04/01/2009 - "Research on LP biology has contributed to the development of a first-generation S1P receptor modulator that has entered phase III clinical trials for the treatment of multiple sclerosis. "
07/01/2015 - "Sphingosine 1-phosphate receptor modulators in multiple sclerosis."
05/01/2015 - "Ponesimod is an orally active selective sphingosine-1-phosphate receptor 1 modulator under investigation for the treatment of multiple sclerosis. "
|2.||Autoimmune Diseases (Autoimmune Disease)
02/01/2012 - "The therapeutic value of modulating S1P metabolism and S1P receptor function is currently tested in clinical trials and holds great promise for treatment of different autoimmune diseases. "
02/01/2014 - "This multiple-ascending-dose study investigated the safety, tolerability, pharmacokinetics, and pharmacodynamics of ponesimod, an S1P1 receptor modulator and a potential new treatment for autoimmune diseases. "
07/01/2014 - "The selective S1P1 receptor agonist ponesimod, which is in development for the treatment of autoimmune diseases, efficiently reduces peripheral lymphocyte counts and displays efficacy in animal models of autoimmune disease. "
01/15/2014 - "SYL-1119 is a sphingosine-1-phosphate receptor 1 modulator for the treatment of autoimmune disease with better selectivity, while SYL-1119-P is its active phosphate. "
05/24/2013 - "Synthetic sphingosine 1-phosphate receptor 1 modulators constitute a new class of drugs for the treatment of autoimmune diseases. "
08/01/2015 - "In addition, these effects of S1P in tumor progression are S1P receptor-dependent, and Survivin plays a key role in S1P tumorigenesis. "
10/01/2014 - "Five sphingosine-1-phosphate receptors (S1PR): S1PR1, S1PR2, S1PR3, S1PR4 and S1PR5 (S1PR1-5) have been shown to be involved in the proliferation and progression of various cancers. "
11/01/2011 - "Targeting sphingosine-1-phosphate receptors in cancer."
01/01/2011 - "These recent findings provide further basis for S1P receptor subtype-specific, novel therapeutic tactics for individualized treatment of patients with cancer."
05/01/2008 - "A case report of a renal mixed epithelial and stromal tumor in a heterozygous S1P2 receptor deficient mouse."
05/01/2015 - "Recent studies suggest that sphingosine-1-phosphate receptor subtype 2 (S1PR2) signaling in endothelial cells (ECs) play a critical role in endothelial inflammation. "
08/01/2015 - "Sphingosine-1-phosphate receptors (S1PRs) are important regulators of vascular permeability, inflammation, angiogenesis and vascular maturation. "
08/01/2015 - "Sphingosine 1-phosphate receptor 2 (S1PR2) modulates endotoxin-induced inflammation in endothelium. "
05/01/2015 - "Sphingosine-1-phosphate receptor subtype 2 signaling in endothelial senescence-associated functional impairments and inflammation."
01/01/2014 - "Development of sphingosine-1-phosphate receptor 1 (S1P1) modulators to dampen inflammation and its sequelae is becoming increasingly promising for treating medical conditions characterized by significant immunopathology. "
|5.||Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental)
02/01/2013 - "Sphingosine 1-phosphate receptor 1 (S1P(1)) upregulation and amelioration of experimental autoimmune encephalomyelitis by an S1P(1) antagonist."
12/01/2005 - "FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration."
03/01/2011 - "Fingolimod (FTY720), a sphingosine 1-phosphate (S1P) receptor modulator, inhibits S1P-dependent lymphocyte egress from secondary lymphoid organs and is highly effective in experimental autoimmune encephalomyelitis (EAE) in mice. "
03/01/2011 - "Fingolimod (FTY720), sphingosine 1-phosphate receptor modulator, shows superior efficacy as compared with interferon-β in mouse experimental autoimmune encephalomyelitis."
08/01/2011 - "There has been poor translation for the use of immunosuppressive agents from experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS), into the treatment of MS. This may be due to the fact that most EAE studies examine prophylactic, pre-treatment regimes that prove to be therapeutically-ineffective in long-established, often progressive, MS. FTY720 (fingolimod/Gilenya) is a sphingosine-1-phosphate receptor modulator. "
|2.||sphingosine 1-phosphate (sphingosine-1-phosphate)
|8.||Amyloid (Amyloid Fibrils)
|3.||Drug Therapy (Chemotherapy)
|4.||Transplantation (Transplant Recipients)
|5.||Homologous Transplantation (Allograft)